Dominic G Rothwell
Overview
Explore the profile of Dominic G Rothwell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tivey A, Lee R, Clipson A, Hill S, Lorigan P, Rothwell D, et al.
Cell Rep Med
. 2024 Sep;
5(9):101736.
PMID: 39293399
Treatments for cancer patients are becoming increasingly complex, and there is a growing desire from clinicians and patients for biomarkers that can account for this complexity to support informed decisions...
2.
Horne A, Harada K, Brown K, Lee Min Chua K, McDonald F, Price G, et al.
J Thorac Oncol
. 2024 Sep;
19(11):1580.
PMID: 39243249
No abstract available.
3.
Behrouzi R, Clipson A, Simpson K, Blackhall F, Rothwell D, Dive C, et al.
Trends Mol Med
. 2024 Sep;
31(1):64-78.
PMID: 39232927
Small cell lung cancer (SCLC) is highly aggressive with poor prognosis. Despite a relative prevalence of circulating tumour DNA (ctDNA) in SCLC, liquid biopsies are not currently implemented, unlike non-SCLC...
4.
Conway A, Pearce S, Clipson A, Hill S, Chemi F, Slane-Tan D, et al.
Nat Commun
. 2024 Apr;
15(1):3292.
PMID: 38632274
Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy. Predicting tissue-of-origin (TOO) molecularly could help refine this diagnosis,...
5.
Horne A, Harada K, Brown K, Lee Min Chua K, McDonald F, Price G, et al.
J Thorac Oncol
. 2024 Apr;
19(8):1164-1185.
PMID: 38615939
Owing to major advances in the field of radiation oncology, patients with lung cancer can now receive technically individualized radiotherapy treatments. Nevertheless, in the era of precision oncology, radiotherapy-based treatment...
6.
Morgan R, Clamp A, White D, Price M, Burghel G, Ryder W, et al.
Clin Cancer Res
. 2023 Feb;
29(14):2602-2611.
PMID: 36799931
Purpose: A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer (gBRCAm-HGSOC). The feasibility of a second maintenance course of...
7.
Chemi F, Pearce S, Clipson A, Hill S, Conway A, Richardson S, et al.
Nat Cancer
. 2022 Aug;
3(10):1260-1270.
PMID: 35941262
Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and transcriptomic heterogeneity. Subtypes based upon predominant transcription factor expression have been defined that, in mouse models and cell lines,...
8.
Frizziero M, Kilgour E, Simpson K, Rothwell D, Moore D, Frese K, et al.
Clin Cancer Res
. 2022 Jan;
28(10):1999-2019.
PMID: 35091446
Poorly differentiated neuroendocrine carcinomas (PD-NEC) are rare cancers garnering interest as they become more commonly encountered in the clinic. This is due to improved diagnostic methods and the increasingly observed...
9.
Chemi F, Mohan S, Guevara T, Clipson A, Rothwell D, Dive C
Front Oncol
. 2021 May;
11:672195.
PMID: 34026650
Circulating tumor cells (CTCs) play a causal role in the development of metastasis, the major cause of cancer-associated mortality worldwide. In the past decade, the development of powerful cellular and...
10.
Gardner L, Warrington J, Rogan J, Rothwell D, Brady G, Dive C, et al.
Nanoscale Horiz
. 2020 Aug;
5(11):1476-1486.
PMID: 32853302
The spontaneous adsorption of biomolecules onto the surface of nanoparticles (NPs) in complex physiological biofluids has been widely investigated over the last decade. Characterisation of the protein composition of the...